With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.